tldrdailynews.com logo
Tag

Eli Lilly

All articles tagged with #eli lilly

Amazon Pharmacy Lands Lilly’s Foundayo GLP-1 Pill for Same-Day Delivery
business1 day ago

Amazon Pharmacy Lands Lilly’s Foundayo GLP-1 Pill for Same-Day Delivery

Amazon Pharmacy will offer Eli Lilly’s new oral GLP-1 drug Foundayo with real-time availability and transparent pricing (insurance as low as $1/day or $25/mo; cash $5/day or $149/mo; automatic coupons), plus Same-Day Delivery nationwide and pharmacist-supported in-office kiosks at select One Medical locations, expanding access from about 3,000 to 4,500 cities by year-end; remote areas will have next-day to three-day delivery.

via Business Wire|
#amazon-pharmacy#business#eli-lilly
Lilly inks AI-driven oral drug deal with Insilico worth up to $2.75B
business12 days ago

Lilly inks AI-driven oral drug deal with Insilico worth up to $2.75B

Eli Lilly and Insilico Medicine have agreed to a commercialization deal valued at up to $2.75 billion (including $115 million upfront) to develop, manufacture, and bring to market Insilico’s AI-discovered preclinical oral drug candidates, with milestones tied to regulatory and commercial success. The companies deny rumors of a full acquisition, and specific asset details aren’t disclosed, though a GLP-1 candidate has been licensed to an undisclosed partner.

via statnews.com|
#ai-drug-discovery#biobucks#business
Lilly inks $2.75B deal to commercialize AI‑discovered drugs with Insilico
business12 days ago

Lilly inks $2.75B deal to commercialize AI‑discovered drugs with Insilico

Eli Lilly agreed to a $2.75 billion deal to bring AI‑discovered drugs from Insilico Medicine to the global market, with $115 million upfront and remaining milestones plus royalties. Insilico has developed about 28 AI‑driven drug candidates, roughly half in clinical stages, and will join Lilly’s Gateway Labs; the collaboration—dating to a 2023 AI software license—aims to accelerate discovery across multiple disease areas as Lilly expands its AI‑driven R&D and China investment strategy.

via CNBC|
#ai-drug-discovery#business#eli-lilly
Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial
business23 days ago

Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial

Eli Lilly's next‑generation obesity drug retatrutide showed strong Phase 3 results in Type 2 diabetes, lowering A1C by about 1.7%–2% at 40 weeks and achieving roughly 16.8% weight loss at the highest dose among patients who stayed on treatment, with a tolerable safety profile. The company has not filed for approval yet and plans additional Phase 3 trials, pursuing retatrutide as a key pillar of its obesity/diabetes portfolio alongside Zepbound and orforglipron, as Novo Nordisk races to catch up.

via CNBC|
#a1c#business#eli-lilly
Lilly Surges on GLP-1 Demand, Sets 2026 Revenue Outlook
business2 months ago

Lilly Surges on GLP-1 Demand, Sets 2026 Revenue Outlook

Eli Lilly beat Q4 estimates with adjusted EPS of $7.54 and revenue of $19.29B (up 43%), and issued 2026 guidance of $80-83B in revenue and $33.50-35 in EPS, powered by robust GLP-1 demand for Zepbound and Mounjaro. U.S. sales reached $12.9B with volume up about 50% while prices moderated. Lilly faces competition from Novo Nordisk and highlighted pricing steps under a 2026 deal with Medicare/Medicaid and a direct-to-consumer TrumpRx platform, with most pricing moves expected early in 2026 and volume growth ramping in the second half. The company is also pursuing an oral weight-loss drug, orforglipron, later this year.

via CNBC|
#business#earnings#eli-lilly
Medicare tailwinds could accelerate Lilly’s obesity-pill rollout
business2 months ago

Medicare tailwinds could accelerate Lilly’s obesity-pill rollout

Eli Lilly CEO Dave Ricks says Medicare coverage of obesity treatments later this year could be a major catalyst for the launch of orforglipron, with a full rollout planned in Q2 and price reductions expected in the second half under Trump-era deals; the move could expand access to 20–30 million beneficiaries and follows strong early demand for competitor Wegovy, a GLP-1 obesity pill.

via CNBC|
#business#eli-lilly#glp-1
Lilly bets on a $3.5B PA plant to accelerate next-gen obesity drugs
business2 months ago

Lilly bets on a $3.5B PA plant to accelerate next-gen obesity drugs

Eli Lilly announced a $3.5 billion manufacturing plant in Pennsylvania’s Lehigh Valley to produce its next-generation obesity therapies, including the experimental drug retatrutide. The new facility, Lilly’s fourth major U.S. site, is slated to start this year and become operational in 2031, creating about 850 local jobs and 2,000 construction roles, as the company seeks to expand capacity amid strong GLP-1 market competition and ongoing push to secure drug supply.

via CNBC|
#business#eli-lilly#glp-1
Lilly and Novo Accused of Blocking Telehealth to Suppress Cheaper GLP-1 Versions
business2 months ago

Lilly and Novo Accused of Blocking Telehealth to Suppress Cheaper GLP-1 Versions

A lawsuit filed by Strive Specialties alleges Eli Lilly and Novo Nordisk blocked telehealth partners to curb compounded GLP-1 therapies, potentially impacting about 1.5 million U.S. patients who rely on cheaper, personalized versions of Wegovy/Ozempic. The plaintiffs say these agreements limit prescriber choice and patient access, while the drugmakers argue the deals target mass-produced copies. Novo Nordisk has highlighted the past Hims & Hers partnership ended after compounded Wegovy issues, and Lilly labeled the suit a bid to divert attention from Strive’s own conduct. The case underscores ongoing tensions between compounded vs. branded GLP-1 drugs, access, and pricing in the weight‑loss market.

via Sherwood News|
#business#compounding#eli-lilly